anti-PD-1 antibody

Phase 2Biologic

Boehringer Ingelheim

anti-PD-1 antibody is one of 115 biologic programs targeting Chronic Hepatitis b. It is currently in Phase 2.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis BRecruiting

Malignant TumorsRecruiting

Relapsed or RefractoryRecruiting

Advanced/metastatic Solid TumorsActive, not recruiting

Patients With Advanced Solid TumorsRecruiting

Chronic Hepatitis BPhase 2

Recruiting

Malignant TumorsPhase 1

Recruiting

Relapsed or RefractoryPhase 2

Recruiting

Advanced/metastatic Solid TumorsPhase 1

Active, not recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

25 2

Tecentriq

Roche

Phase 2

4 3

Halaven

Eisai

Phase 2

2 4

Perjeta

Roche

Phase 2

2 5

Cyramza

Eli Lilly

Phase 2

1 6

Lazcluze

Johnson & Johnson

Phase 2

1 7

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 8

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2 9

Carboplatin AUC-5

Merck & Co.

Phase 2

1 10

Utidelone

BBeijing Biostar Pharmaceuticals Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Malignant Tumors

NCT05631886

Phase 1Active, not recruiting

Advanced/metastatic Solid Tumors

NCT05631899

Phase 2Recruiting

Chronic Hepatitis B

NCT05769816

Phase 2Recruiting

Chronic Hepatitis B

NCT05771402

Q3 2027

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05204862

Q1 2028

PreclinicalRecruiting

Pancreatic Cancer

NCT07892573

Clinical

Trials by Indication[1]

Pancreatic Cancer4 trials

SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients

Terminated·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03716596·8 enrolled

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Unknown status·—·Phase 1/2·NCT03989310·50 enrolled

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Unknown status·SShixiu Wu·Phase 2·NCT03374293·21 enrolled

Show 1 more trial

Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy

Recruiting·NNingbo Medical Center Lihuili Hospital·Preclinical·NCT07892573·27 enrolled

Immunotherapy2 trials

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Completed·—·Phase 1/2·NCT03757858·40 enrolled

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Unknown status·—·Phase 1/2·NCT04004234·20 enrolled

Chronic Hepatitis b2 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05769816·120 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Recruiting·TTiumBio Co., Ltd.·Phase 1/2·NCT05204862·240 enrolled

Triple-Negative Breast Cancer1 trial

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Unknown status·—·Phase 2·NCT05402722·30 enrolled

10 more indications

Gastroesophageal Junction Adenocarcinoma1 trial

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Unknown status·—·Phase 2·NCT04098796·30 enrolled

Phase 11 trial

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Completed·IIntensity Therapeutics, Inc.·Phase 1/2·NCT03058289·111 enrolled

Relapsed or Refractory1 trial

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Recruiting·HHan weidong·Phase 1/2·NCT02961101·250 enrolled

Malignant Mesothelioma1 trial

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Terminated·—·Phase 1/2·NCT03393858·10 enrolled

Malignant Tumors1 trial

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Recruiting·—·Phase 1·NCT05631886·10 enrolled

Advanced/Metastatic Solid Tumors1 trial

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Active, not recruiting·—·Phase 1·NCT05631899·9 enrolled

Lymphoma1 trial

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Unknown status·—·Phase 1·NCT03991559·20 enrolled

Advanced Malignant Tumors1 trial

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Completed·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT05223231·26 enrolled

Solid Tumor1 trial

Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors

Suspended· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05155332·190 enrolled

Ovarian Cancer1 trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Manganese-primed Immunochemotherapy in Subjects With Advanced Ovarian Cancer

Recruiting·CChinese PLA General Hospital·Phase 3·NCT07822646·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for anti-PD-1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-PD-1 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

anti-PD-1 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q1 2028

Trials by Indication[1]

Pancreatic Cancer4 trials

Immunotherapy2 trials

Chronic Hepatitis b2 trials

Patients With Advanced Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Phase 11 trial

Relapsed or Refractory1 trial

Malignant Mesothelioma1 trial

Malignant Tumors1 trial

Advanced/Metastatic Solid Tumors1 trial

Lymphoma1 trial

Advanced Malignant Tumors1 trial

Solid Tumor1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News